Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Strong statin therapy reverses plaque build-up in arteries

24.09.2002


Reducing bad cholesterol to below "optimal" levels reversed the accumulation of artery-clogging plaque, according to a study in today’s rapid access issue of Circulation: Journal of the American Heart Association. When atherosclerotic plaque builds up in the arteries it can cause a heart attack or stroke.



People with known heart disease or a major risk factor, such as diabetes, are counseled to reduce their low-density lipoprotein (LDL) cholesterol ("bad" cholesterol) below 100 milligrams/deciliter (mg/dL) of blood. The goal for patients whose only risk factor is high cholesterol is usually below 130 mg/dL. Statin drugs are commonly used to lower total and LDL cholesterol.

There has been some question recently, however, whether more aggressive LDL lowering would confer an even greater benefit, says lead author Allen J. Taylor, M.D., director of cardiovascular research at Walter Reed Army Medical Center in Washington, D.C.


In addition, there is a question of whether factors besides cholesterol-lowering figure into the overall benefit from statin therapy. Besides affecting cholesterol, statins may also affect levels of inflammation or the degree of artery thickening.

"This is the first comparison of two statin drugs in a general population that looked at more than their cholesterol-lowering abilities," says Taylor.

Researchers recruited 161 patients (average age 60, 71 percent men) who were candidates for statin therapy. About half had known cardiovascular disease. Of these patients, 138 completed the study in which they received either 40 milligrams (mg) of the natural drug pravastatin, or 80 mg of relatively new synthetic statin called atorvastatin.

After 12 months, those receiving pravastatin treatment had a 27.5 percent drop in their LDL cholesterol compared to a 48.5 percent reduction in LDL for people treated with the higher dose of atorvastatin. The pravastatin group’s LDL was reduced to 110 mg/dL while the atorvastatin group’s LDL level was 76 mg/dL.

Researchers used ultrasound to compare the thickness of the carotid arteries (major arteries in the neck that supply blood to the brain) before treatment, after six months, and after one year of therapy. The amount of plaque in the carotid arteries is considered a good indicator of the amount of atherosclerosis throughout the body.

The researchers found that many patients had a net decrease in carotid artery thickness – 54 percent of atorvastatin patients and 39 percent of pravastatin patients.

Patients who received moderate treatment with pravastatin showed a slight progression in the thickness of the atherosclerosis in their carotid arteries (from an average of .615 mm at baseline to an average of .640 mm thickness at 12 months). Those who received atorvastatin treatment had a decrease (from an average of .625 mm to an average of .591 mm).

"Atherosclerosis is a progressive disease that takes years to develop and continues to get worse over time unless treated," Taylor explains. "Previous studies found that patients in whom plaque stabilized – or stopped progressing – had the lowest risk of heart attacks and other cardiovascular disease problems. In general, past studies have shown that regression is uncommon."

"We need to carefully define at what point lower LDL values have the greatest benefit in lowering the risk of heart disease. This study would suggest that LDL values much lower than 100 mg/dL appears better than a value of around 100," he says.

In an accompanying editorial, Prediman K. Shah, M.D., director of the division of cardiology and atherosclerosis research center at Cedars Sinai Medical Center in Los Angeles, Calif., says, "The data provided by Taylor are of potential interest and could have significant implications for clinical practice. However, before we conclude that more LDL-lowering means less atherosclerosis progression or clinical events, more in depth research is necessary."

Shah points to several large scale trials that are measuring the effect of moderate vs. aggressive cholesterol lowering on coronary plaque and cardiac events that should provide additional valuable information in the near future.


Co-authors include Steven M. Kent, M.D.; Patrick J. Flaherty, D.O.; Louis C. Coyle, D.O.; Thor T. Markwood M.D.; and Marina N. Vernalis, D.O.

CONTACT: For journal copies only,
please call: (214) 706-1396
For other information, call:
Carole Bullock: (214) 706-1279
Bridgette McNeill: (214) 706-1135

Carole Bullock | EurekAlert!
Further information:
http://www.americanheart.org/

More articles from Health and Medicine:

nachricht New nanomedicine slips through the cracks
24.04.2019 | University of Tokyo

nachricht Sugar entering the brain during septic shock causes memory loss
23.04.2019 | Rensselaer Polytechnic Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Energy-saving new LED phosphor

The human eye is particularly sensitive to green, but less sensitive to blue and red. Chemists led by Hubert Huppertz at the University of Innsbruck have now developed a new red phosphor whose light is well perceived by the eye. This increases the light yield of white LEDs by around one sixth, which can significantly improve the energy efficiency of lighting systems.

Light emitting diodes or LEDs are only able to produce light of a certain colour. However, white light can be created using different colour mixing processes.

Im Focus: Quantum gas turns supersolid

Researchers led by Francesca Ferlaino from the University of Innsbruck and the Austrian Academy of Sciences report in Physical Review X on the observation of supersolid behavior in dipolar quantum gases of erbium and dysprosium. In the dysprosium gas these properties are unprecedentedly long-lived. This sets the stage for future investigations into the nature of this exotic phase of matter.

Supersolidity is a paradoxical state where the matter is both crystallized and superfluid. Predicted 50 years ago, such a counter-intuitive phase, featuring...

Im Focus: Explosion on Jupiter-sized star 10 times more powerful than ever seen on our sun

A stellar flare 10 times more powerful than anything seen on our sun has burst from an ultracool star almost the same size as Jupiter

  • Coolest and smallest star to produce a superflare found
  • Star is a tenth of the radius of our Sun
  • Researchers led by University of Warwick could only see...

Im Focus: Quantum simulation more stable than expected

A localization phenomenon boosts the accuracy of solving quantum many-body problems with quantum computers which are otherwise challenging for conventional computers. This brings such digital quantum simulation within reach on quantum devices available today.

Quantum computers promise to solve certain computational problems exponentially faster than any classical machine. “A particularly promising application is the...

Im Focus: Largest, fastest array of microscopic 'traffic cops' for optical communications

The technology could revolutionize how information travels through data centers and artificial intelligence networks

Engineers at the University of California, Berkeley have built a new photonic switch that can control the direction of light passing through optical fibers...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

Fraunhofer FHR at the IEEE Radar Conference 2019 in Boston, USA

09.04.2019 | Event News

 
Latest News

Proteins stand up to nerve cell regression

24.04.2019 | Life Sciences

New sensor detects rare metals used in smartphones

24.04.2019 | Life Sciences

Controlling instabilities gives closer look at chemistry from hypersonic vehicles

24.04.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>